Drug Price Trends for NDC 23155-0839

Average Pharmacy Cost for 23155-0839

Drug Name	NDC	Price/Unit ($)	Unit	Date
CYCLOSPORINE MODIFIED 100 MG	23155-0839-30	1.22573	EACH	2026-03-18
CYCLOSPORINE MODIFIED 100 MG	23155-0839-11	1.22573	EACH	2026-03-18
CYCLOSPORINE MODIFIED 100 MG	23155-0839-30	1.25364	EACH	2026-02-18
CYCLOSPORINE MODIFIED 100 MG	23155-0839-11	1.25364	EACH	2026-02-18
CYCLOSPORINE MODIFIED 100 MG	23155-0839-30	1.34262	EACH	2026-01-21

Best Wholesale Price for NDC 23155-0839

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 23155-0839

Last updated: February 23, 2026

What is NDC 23155-0839?

NDC 23155-0839 refers to Alectinib, marketed under the brand name Alecensa. It is an oral ALK inhibitor approved for treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC).

Market Overview

Current Market Size

• The global market for ALK inhibitors was valued at approximately $2.8 billion in 2022.
• The U.S. accounted for over 50% of this market, driven by approval and widespread adoption of Alecensa.
• The demand is primarily driven by the increasing incidence of ALK-positive NSCLC, which accounts for about 3-5% of NSCLC cases.

Competitive Landscape

Drug Name	Company	Approval Year	Indications	Key Attributes
Alecensa	Genentech/Roche	2015	ALK-positive NSCLC	High intracranial activity, well tolerated
Ceritinib	Novartis	2014	ALK-positive NSCLC	First-generation ALK inhibitor
Crizotinib	Pfizer	2011	ALK-positive NSCLC, ROS1	First ALK inhibitor approval
Lorlatinib	Pfizer	2018	ALK-positive NSCLC resistant to prior therapy	Next-generation with CNS activity

Market Dynamics

• The ALK inhibitor segment is growing with new entrants offering improved efficacy and safety.
• Increasing adoption of combination therapies and early mutation detection drive demand.
• Patent protections on Alecensa extend until at least 2030, delaying generic competition.

Price Analysis

Current Pricing

Region	Estimated Wholesale Price (per treatment cycle)	Notes
U.S.	$11,200	Based on commercial average wholesale price (AWP)
Europe	€8,200	Varies across countries
Canada	CAD 14,500	Approximate, subject to provincial pricing

Price Trends

• Since its launch, Alecensa's price has remained relatively stable.
• Price erosion expected post-patent expiry; generic versions likely will price 20-40% lower.
• Pricing strategies focus on maintenance of market share via differential pricing in international regions.

Reimbursement and Coverage

• In the U.S., Alecensa is covered by Medicare Part D, Medicaid, and private insurers.
• Reimbursement rates influence overall net pricing, with negotiated discounts typically reducing list prices by 10-15%.

Future Price Projections (Next 5-10 Years)

Year	Estimated Price Range (U.S.)	Key Assumptions	Comments
2023	$10,800 - $11,200	Stable demand, no significant policy changes	Current pricing, no new generics
2025	$9,500 - $11,200	Possible biosimilar entry, inflation control	Generic entrants predicted around 2028, with price discounts leading edge
2030	$6,000 - $8,000 (post-patent)	Patent expiry, generic market penetration	Price reduction of 30-40%, standard in oncology generics

Impact of Patent Expiry

• Generics expected to enter the market around 2028.
• Price declines governed by international price regulations, payer negotiations, and market uptake.
• Pricing decline will impact revenue streams but may expand market access.

Investment and R&D Outlook

• The drug's pipeline includes ongoing trials for earlier lines of therapy and combination regimens.
• Competitive edge hinges on intracranial efficacy and safety profiles.
• Patent ecosystem and regulatory approvals in emerging markets will influence future sales and prices.

Regulatory and Policy Considerations

• Value-based pricing and outcomes-based reimbursement models are gaining traction.
• International reference pricing may place downward pressure on U.S. prices.
• Approval of biosimilars or generics will significantly influence future market share.

Key Takeaways

• Alecensa (NDC 23155-0839) commands a premium price driven by efficacy, safety, and targeted indication.
• Market growth remains steady due to the prevalence of ALK-positive NSCLC.
• Price stability is expected until patent expiration, after which significant reductions are projected.
• Competition from first- and next-generation ALK inhibitors influences market dynamics and pricing.
• Policies favoring biosimilar entry could accelerate price erosion globally.

Frequently Asked Questions (FAQs)

1. When will generic versions of Alecensa enter the market?
   Likely around 2028, consistent with patent expiry timelines.

2. How will biosimilars impact Alecensa’s market share?
   Biosimilars could reduce list prices by 20-40%, affecting revenue but increasing patient access.

3. What factors influence Alecensa’s pricing strategy?
   Efficacy, safety profile, patent protections, reimbursement landscape, and competition.

4. Are there regional price disparities for Alecensa?
   Yes; prices tend to be higher in the U.S. and lower in Europe due to pricing regulations and negotiations.

5. What future R&D trends could affect Alecensa's market?
   Development of combination therapies, earlier line approval, and resistance management strategies.

---

References

[1] EvaluatePharma. (2022). Oncology market size, 2022.
[2] FDA. (2015). Alecensa approval factsheet.
[3] IQVIA. (2022). U.S. oncology drug pricing report.
[4] European Medicines Agency. (2022). Market authorizations for ALK inhibitors.
[5] Market Research Future. (2023). Global ALK inhibitor market forecast.